more

PDL BioPharma (PDLI)

(Delayed Data from NSDQ)

$2.47 USD

0.00 (0.00%)

Updated Dec 30, 2020 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study

by Zacks Equity Research Published on April 17,2019

Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.

biotechs

Kamada to Begin Phase III Study for Inhaled AAT Product in 2H

by Zacks Equity Research Published on April 17,2019

Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.

biotechs

Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up

by Zacks Equity Research Published on April 16,2019

Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.

biotechs

Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises

by Zacks Equity Research Published on April 16,2019

Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.

Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study

by Zacks Equity Research Published on April 15,2019

Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.

medical

PDL BioPharma (PDLI) Up 9.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research Published on April 13,2019

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PDLINo Net Change

Acorda to Gain From Inbrija Sales and Neurological Pipeline

by Zacks Equity Research Published on April 11,2019

Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.

biotechs

PDL BioPharma (PDLI) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research Published on April 10,2019

Does PDL BioPharma (PDLI) have what it takes to be a top stock pick for momentum investors? Let's find out.

PDLINo Net Change

Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

by Zacks Equity Research Published on April 09,2019

Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.

biotechs

Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study

by Zacks Equity Research Published on April 05,2019

Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.

biotechs

Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down

by Zacks Equity Research Published on April 02,2019

Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.

biotechs

Blueprint Medicines Expediates Filings for Key Candidates

by Zacks Equity Research Published on March 28,2019

Blueprint Medicines (BPMC) revs up the regulatory filling plans for its cancer candidates, avapritinib and BLU-667.

biotechs

Agios (AGIO) Surges More Than 40% Year to Date: Here's Why

by Zacks Equity Research Published on March 27,2019

Agios' (AGIO) first wholly owned precision medicine, Tibsovo, has been picking up the sales pace since its FDA approval last year with strong sequential growth delivered in Q4.

medical

Agios Gains Breakthrough Therapy Status for Tibsovo Combo

by Zacks Equity Research Published on March 27,2019

Agios (AGIO) receives a Breakthrough Therapy designation for Tibsovo combo to treat the newly diagnosed acute myeloid leukemia in adult patients with an IDH1 mutation.